10. 07. 2021

Phesi Big Data Analysis of Over 200,000 Hepatitis B and C Patients Identifies Typical Patient to Help Drive Forward Disease Elimination Goals

Read more
08. 02. 2021

Sensyne grows medical research dataset to 60 million patients

Oxford, U.K. 02 August 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the ethical Clinical Al company, today announces that it has reached a milestone of access to a combined clinical research, clinical trial and real world de-identified and anonymised dataset of over 60 million patients. This enlarged dataset results from both Sensyne’s investment in virtual clinical development company, Phesi Inc. in January 2021, and the progress made by Sensyne and Phesi in building their respective data platforms…

Read more
01. 05. 2021

Phesi and Sensyne Health agree collaboration to advance development of synthetic arms in clinical trials

January 5th, 2021 – Connecticut, USA – Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, today announced it has entered into an exclusive strategic collaboration with clinical AI technology company, Sensyne Health (LSE: SENS), which is making an equity investment of $10 million in Phesi…

Read more
09. 11. 2020

Phesi data show clinical trial suspensions continue to rise as covid-19 impact on development persists

Connecticut, USA – Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, today announced it has entered into an exclusive strategic collaboration with clinical AI technology
company, Sensyne Health…

Read more